Good appointments. Dr Rodenburger helped achieve the FDA...

Good appointments. Dr Rodenburger helped achieve the FDA approval for Clinuvel in the past with EPP, also knows Vitiligo and obtaining FDA approval in this blockbuster should be easier as the drug is already approved with a long track record of safety and showing efficacy would appear to be quite simple relatively. Approval for a new indication easier than a whole new drug application, with safety well established, so hopefully this becomes the standard of care in just a handful of years.

US investor relations also good, first job needs to be the basic upgrade from the obscure pink sheets so attracting investors will be an easier task for him. Clinuvel said it only took one investor buying a lot of shares in Sep 2021 to take the price over $40 and the investment case is much stronger now with the Phase 3 trial running and stated revenue targets of $490 - $570 Million USD in years 1-2 on top of an already very profitable enterprise which doesn't have to share profits with 'big Pharma'. Great scenario just calculate likelihood of Vitiligo approval, pretty good chance IMO and only one analyst has done this and come up with a PT ~$50. Mega Blockbuster Stroke and everything else you get for free with CUV and many small loss making Biotechs with high valuations just on the hope that their Phase 1 or 2 will one day become a blockbuster like Stroke.

Not using the buyback at all is quite ridiculous, they had good momentum with the announcement and follow up statement that the buyback would be expanded if shorters didn't 'get the message' and then great news potential competitor Disc flunked their EPP trial. All this led to great buying and shorts had to pump in enormous amounts of fake Sell liquidity to control the price according to ASIC data. Since then they have continued to drop the price like last Friday, a 6% drop which was 3% below VWAP shows massive manipulation designed to scare investors, shorts have a clear history with doing this at CUV and the company just let it happen last week when they have the tools to stop this now (over time). Still manipulating the closing price to 3% below VWAP might even be enough to attract ASIC attention if they have any heartbeat at all but that is a long shot - still the shorting game is stacked in favour of shorters they can take 6% off with fake liquidity and circular trades in one day but CUV can only buyback up to a limit of 5% above previous 5 days average VWAP. That is why the buyback will work over time but it needs to get moving with some aggression and then maintain that momentum (and maybe management buying would also send a signal). Either way it's a great entry point for new investors and should make new US recruit Mr Clouston's job quite easy in the States. It shouldn't take too many large investors to get this thing moving, unless shorters want to make cash printing CUV the most shorted company in Australia against all logic.

All IMO DYOR